A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

<h4>Background</h4> Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and some acute myeloid leukemia (AML). However, the long-term safety of VEN in large sample population was...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yang Yang, Yamin Shu, Guosong Chen, Yanchao Yin, Feie Li, Juan Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2022-01-01
Edice:	PLoS ONE
On-line přístup:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728853/?tool=EBI
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!